Botanix Pharmaceuticals Limited (BXPHF) Comparison with companies in other sectors?

Botanix Pharmaceuticals Limited has a share price of 1.96B. You can analyze Botanix Pharmaceuticals Limited (BXPHF) competitors across different market sectors through stock heatmaps.

What are BXPHF's NET and operating margins?

Botanix Pharmaceuticals Limited (BXPHF) operating margin is around -6.94, and net profit margin is approximately -6.70 as of the latest reports.

In what way does BXPHF's earnings per share (EPS) trend reflect its financial momentum?

Botanix Pharmaceuticals Limited (BXPHF) EPS is -0.01 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Botanix Pharmaceuticals Limited is -14.13, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Botanix Pharmaceuticals Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Botanix Pharmaceuticals Limited like P/E which is -24.28, P/B which is 3.10, and PEG which is 0.61. Compare them with sector averages to evaluate if the stock is priced fairly.

Botanix Pharmaceuticals Limited

BXPHF•PNK

Healthcare

Biotechnology

$0.14

$0.00(0.00%)

Fundamental Analysis of Botanix Pharmaceuticals Limited (BXPHF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.01

P/E Ratio

-14.13

ROE

-0.18%

Net Margin

-6.70%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$277.11M

Shares OutstandingTotal number of shares issued

$1.96B

Book Value/ShareNet worth per share

$0.07

Revenue/ShareAnnual revenue per share

$0.001

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.01

Net MarginNet income as percentage of revenue

-670.20%

Operating MarginOperating income as percentage of revenue

-693.76%

ROEReturn on shareholders' equity

-18.00%

ROAReturn on total assets

-12.33%

ROCEReturn on capital employed

-13.20%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.01

Cash/ShareCash and equivalents per share

$0.05

FCF YieldFree cash flow as percentage of market cap

-5.45%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for BXPHFFinancial Ratios Analysis details for BXPHF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BXPHFSector Benchmarking details for BXPHF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Botanix Pharmaceuticals Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Botanix Pharmaceuticals Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Botanix Pharmaceuticals Limited's unique business strengths and challenges.

Key Financial Metrics for Botanix Pharmaceuticals Limited

For Botanix Pharmaceuticals Limited, essential financial indicators include EPS -0.01, PE -14.13, and ROE -0.18. These key ratios reveal insights into Botanix Pharmaceuticals Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Botanix Pharmaceuticals Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Botanix Pharmaceuticals Limited

Metrics like Net Margin -670.20% and ROA -12.33% shed light on how well Botanix Pharmaceuticals Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Botanix Pharmaceuticals Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Botanix Pharmaceuticals Limited

Using ratios such as P/B Ratio 3.10 and PEG Ratio 0.61, investors can assess whether Botanix Pharmaceuticals Limited is appropriately valued based on its financials and growth potential. These figures, combined with Botanix Pharmaceuticals Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Botanix Pharmaceuticals Limited

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow $-0.01, provide a snapshot of Botanix Pharmaceuticals Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Botanix Pharmaceuticals Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Botanix Pharmaceuticals Limited

Investing in Botanix Pharmaceuticals Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Botanix Pharmaceuticals Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;